NH firm's chewable tablet might offer new help for diabetes patients




PAZ320 is a non-systemic, non-toxic chewable drug candidate that is designed to inhibit enzymes that release glucose from complex carbohydrates in foods during digestion. In a Phase IIa study last year, 45 percent of Type 2 diabetes patients taking metformin responded to PAZ320 with a 40 percent reduction of post-meal glucose in the blood.
CLICK TO VIEW THE SOURCE MATERIAL


Post a comment


You must sign in before you can post comments. If you are experiencing issues with your account please e-mail abuse@unionleader.com.